Lilly gains after data for next-generation weight loss drug

Eli Lilly and Co

21/05/2026 12:28

** Eli Lilly shares LLY.N rise 1.4% to $1,033.23 premarket

** Co says its experimental drug retatrutide helped patients diagnosed with obesity lose more than 28% of their weight over a year and a half in a key trial

** The highest dose of retatrutide helped patients lose 28.3% of their weight on average over 80 weeks

** Incidents of dysesthesia, an abnormal skin sensation,  occurred in 5.1%, 12.3%, and 12.5% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 0.9% with placebo

** Discontinuation rates due to adverse events were 4.1%, 6.9%, 11.3%, with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 4.9% with placebo

** U.S.-listed shares of rival Novo Nordisk NOVOb.CO down 1% before the bell

     ** LLY stock down 5% YTD

 (Reporting by Sriparna Roy in Bengaluru)

 ((Sriparna.Roy@thomsonreuters.com;))